Resources

News

Pure MHC, LLC Announces Launch of its Peptide HLA Immunotherapy Data Resource following Collaboration with LifeNet Health

March 16, 2021

Austin, Texas, USA, March 16, 2021 -- Pure MHC, LLC, a target discovery and development company, today announced the launch of its Peptide HLA Immunotherapy Data Resource (“PHIDR”), built through its collaboration with a trusted provider of transplant solutions and a leader in regenerative medicine, LifeNet Health.

Read More

LifeNet Health LifeSciences highlights innovative human cell- and tissue-based solutions at 2021 Society of Toxicology ToxExpo

March 12, 2021

VIRGINIA BEACH, Va. (March 12, 2021) — LifeNet Health LifeSciences will showcase its portfolio of innovative human cell- and tissue-based research solutions — including the new, all-human Tri-Culture model, thyrocytes for use in 3D models and genotyped human hepatocytes — at the Society of Toxicology (SOT) virtual annual meeting and ToxExpo at booth #1322. LifeSciences provides researchers human-relevant research solutions to optimize outcomes and speed the drug discovery process.

Read More

LifeNet Health LifeSciences has isolated primary human lung cells to aid and accelerate efforts in COVID-19 drug development

February 3, 2021

VIRGINIA BEACH, Va. (Feb. 3, 2021) — LifeNet Health LifeSciences has successfully isolated three types of primary human lung epithelial cells from a single donor. One of the three types, alveolar epithelial type II cells, are of particular interest to scientists due to their applicability for respiratory disease research. LifeNet Health’s scientists have also isolated the bronchial and small airway epithelial cells, which are critical for the first lines of defense in protecting the lungs.

Read More

LifeNet Health launches newly expanded LifeSciences division with innovative solutions for researchers

January 13, 2021

VIRGINIA BEACH, Va.  — LifeNet Health announced today the launch of their newly expanded LifeSciences division which is offering human cell- and tissue-based research solutions through a new website, LNHLifeSciences.org.

Read More

LifeNet Health strengthens its LifeSciences Division with Samsara Sciences asset acquisition

November 07, 2019

Virginia Beach, VA. - LifeNet Health, the world's leading provider of regenerative medicine solutions, has acquired the assets of Samsara Sciences, a San Diego-based life sciences company specializing in human primary liver and kidney cell isolation. The acquisition includes Samsara's equipment, inventory and associated technology.

Read More

LifeNet Health to highlight emerging life sciences research platforms at 2019 BIO International Convention

June 03, 2019

PHILADELPHIA, Pa., (June 3, 2019) — LifeNet Health (Booth #3649) will feature its portfolio of premium research solutions, including high-quality human primary hepatocytes and islets, at the BIO International Convention June 3-6 in Philadelphia.

Read More

LifeNet Health unveils Center of Excellence for research in San Diego

May 14, 2019

SAN DIEGO, Calif. - May 14, 2019 - LifeNet Health, the world’s leading provider of regenerative medicine solutions, today announced the opening of a San Diego facility that stands as a Center of Excellence for its life sciences and tissue-engineering programs, as well as a logistical hub for hospital and surgeon clients on the West Coast.

Read More

LifeNet Health features innovative LifeSciences programs at BIO International Convention

June 04, 2018

Boston, Mass. — June 4, 2018 — LifeNet Health will feature its growing portfolio of unique, high-quality biospecimens for research at the BIO International Convention June 4-7 in Boston (Booth #2414).

Through its LifeSciences Division, the regenerative medicine company is focused on providing transplant- quality organs and tissues, innovative drug discovery platforms and isolated primary cells.

Read More

LifeNet Health’s LifeSciences Division highlights breakthrough 3D assay platform at American Association for Cancer Research (AACR)

April 16, 2018

Chicago, Ill. – April 16, 2018 — LifeNet Health’s HuBiogel microtumor system — the only 3D fully- human tissue-like bioassay platform — provides investigators a vital tool for accelerating preclinical research and drug development. This cell-culture technology is an in vitro biology platform that replicates how cancer cells react to drug treatments in vivo. Unlike common 2D systems, 3D human tumor models enable precise, biologically accurate analysis of multiple endpoints crucial for preclinical and translational oncology programs.

Read More

LifeNet Health’s LifeSciences Division features biologically precise research solutions at Society of Toxicology – TOX EXPO

March 13, 2018

Virginia Beach, Va. – March 13, 2018 — LifeNet Health’s LifeSciences Division (Booth 1661) will highlight its unique capabilities for providing human biospecimens, primary cells and cell-based assay services at Society of Toxicology's 57th Annual Meeting and ToxExpo.

LifeNet Health’s extensive quality programs enhance data, standardize cell preparation and ultimately minimize potential negative impacts on cell health and performance. LifeNet Health’s attendees include leading scientists in the fields of cell isolation, research and culture models.

Read More